Cartesian Therapeutics Q3 EPS $(0.38) Beats $(0.95) Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.95) by 60 percent. This is a 72.46 percent increase over losses of $(1.38) per share
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.95) by 60 percent. This is a 72.46 percent increase over losses of $(1.38) per share from the same period last year.